Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma.

Trial Profile

Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs ALT 801 (Primary) ; Cisplatin
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 23 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Mar 2013 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013, as reported by ClinicalTrials.gov.
    • 12 Mar 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top